Movement Disorders

MeiraGTx's AAV-GAD gene therapy receives FDA RMAT designation, promising innovative treatment for Parkinson's disease through targeted brain infusion.

Panelists discuss how early recognition of dyskinesia symptoms, ongoing patient-clinician communication, and individualized treatment strategies are key to effectively managing Parkinson disease and improving patients’ quality of life.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network. for the week ending May 10, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 9, 2025.

Leveraging the Enroll-HD dataset, recent data revealed consistent links between antidopaminergic medication use and worsened cognitive and motor outcomes in Huntington disease.

Early findings from the ASPIRO trial showed ANPD001 was safe, well-tolerated, and led to marked improvements in motor symptoms and daily functioning.

STN-FUS provided more sustained tremor reduction, improved bradykinesia, and had a higher responder rate at 12 months, though both treatments showed comparable reductions in rigidity and motor scores.

Pagan offered advice on how clinicians can effectively discuss treatment and care plans with patients, especially as new treatments continue to emerge.

New 24-month data further showed dose-dependent lowering of neurofilament light and trends on major end points such as cUHDRS, Total Function Capacity, and Symbol Digit Modalities Test.

Pagan discussed unexpected findings from the InfusON study patient interviews that could influence how neurologists introduce CSAI therapy and how these insights, along with the latest data on MAO-B inhibitors, could shape future treatment combinations for Parkinson disease.

Here's some of what is coming soon to NeurologyLive® this week.

A physician assistant specializing in Parkinson disease talked about how emerging technologies and proactive care models could transform the treatment landscape for Parkinson disease. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 2, 2025.

In this segment, Pagan discussed the benefits of using AI in research and clinical practice, while also highlighting key considerations and cautions for clinicians.

In this segment, Pagan shared strategies to enhance patient adherence and comfort with long-term CSAI use, and offered his perspective on the evolving role of CSAI in managing complex motor fluctuations in Parkinson disease.

Moira Kapral, MD, MSc, reflects on her SEQUINS Hall of Fame recognition, the evolution of brain health equity, and her work addressing disparities in stroke care.

Robert J. Adams, MS, MD, reflects on his SEQUINS Hall of Fame recognition, his work on stroke prevention, and the importance of equity in brain health.

Barbara Vickrey, MD, MPH, discusses her SEQUINS Hall of Fame honor, the evolution of healthcare delivery models, and the role of mentorship in fostering equity in neurology.

Lewis B. Morgenstern, MD, reflects on his SEQUINS Hall of Fame recognition, the importance of health equity research, and his ongoing efforts to reduce stroke disparities.

Cheryl Bushnell, MD, MHS, a professor of neurology at Wake Forest University, discussed her SEQUINS Hall of Fame recognition, her work on sex differences in stroke risk, and her ongoing efforts to improve stroke care equity.

Explore the latest advancements in cell and gene therapies for Parkinson disease, featuring cutting-edge treatments and clinical trial updates from top innovators in the field.

The REGENERATE-PD trial is a phase 2 study assessing the safety and efficacy of the investigational gene therapy AB-1005 in patients with moderate-stage Parkinson disease.

The chief scientific officer of the Parkinson’s Foundation talked about how broad genetic testing through PD GENEration is uncovering valuable prognostic and diagnostic insights in Parkinson disease. [WATCH TIME: 4 minutes]

A new meta-analysis revealed that the efficacy of MRI-guided focused ultrasound decreased over time in essential tremor, with sensory symptoms and unsteadiness as common adverse effects.